Urine Biomarker Detection System

Analytical platform for identification and quantification of disease biomarkers. Enables early disease detection through analysis of specific biological markers.

An in vitro detection system for early diagnosis indicators of diabetic nephropathy in human urine. It features multi-channel composite detection with selected indicator combinations including urinary microalbumin, urinary haptoglobin, and urinary creatinine as an internal standard. The system uses dry biochemistry and immunology methods, allows random urine self-testing without invasive procedures, and supports home-based testing with mobile device image upload for server analysis and professional feedback.

In vitro diagnostic system for early detection of diabetic kidney disease through urine analysis. Combines dry-reagent technology with multi-channel detection of key biomarkers including urine microalbumin, uromodulin, and creatinine. Enables both clinical laboratory quantitative analysis and point-of-care home testing with mobile result upload and remote interpretation.

Integrated biomarker solutions for accelerating research and clinical screening through advanced detection methodologies and real-time monitoring capabilities for disease assessment.

Quantitative urine iodine detection system for early diagnosis of diabetic nephropathy and premature rupture of membranes. The system employs dry-reagent technology with multi-channel composite detection, measuring urine microalbumin, urine haptoglobin, and creatinine as normalization markers. Enables both clinical laboratory analysis and patient self-testing with mobile device result capture and server-based interpretation.

An invention patent product (ZL 2017 1 0507989.9) for in vitro detection of early diagnostic markers of diabetic kidney disease in human urine. It is a Class II urine detection product using dry biochemistry and immunology methods with multi-channel composite detection. The system detects urine microalbumin, urine haptoglobin, and urine creatinine as internal standard. It features non-invasive random urine self-testing, stable dry reagents, and can be used for home self-testing with mobile device result upload for server-based analysis and professional feedback.

Microfluidic systems designed for sensitive detection and quantification of disease biomarkers in biological samples for diagnostic and monitoring purposes.

Quantum dot-based detection platform for in vitro diagnostic testing of urine biomarkers. Enables multi-channel composite analysis for early detection of diabetic nephropathy and premature rupture of membranes through dry-reagent immunoassay technology. Supports both clinical laboratory quantification and point-of-care patient self-testing with mobile device image capture and server-based result analysis.

A diagnostic test kit for measuring microalbumin levels in urine samples. It is used for early detection of kidney disease and monitoring of diabetic patients.

In vitro diagnostic test for combined detection of inflammatory and kidney disease markers in urine samples. Utilizes dry-phase reagent technology with multi-channel analysis to detect urinary microalbumin, uromodulin, and creatinine for early diabetic nephropathy diagnosis. Enables both laboratory quantitative testing and point-of-care self-testing with mobile image capture and server-based result analysis.

Diagnostic test kit for measurement of kidney function biomarkers including creatinine and urea. Facilitates assessment of renal function and detection of kidney disease.

Multi-biomarker screening solution for early-stage cancer identification. Analyzes blood samples to detect cancer-associated molecular signatures. Facilitates timely clinical intervention and improved patient outcomes.